Declining NAD induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging

Summary

Mechanistic mouse study from the Sinclair lab showing that age-related NAD+ decline induces a pseudohypoxic state in which HIF-1α stabilizes under normoxia, disrupting SIRT1-mediated signaling from nucleus to mitochondria and causing mitochondrial-encoded OXPHOS gene expression to fall. Aged (22-month) C57BL/6 mice had ~50% lower muscle NAD+ than young (6-month) controls, paired with reduced mitochondrial respiratory capacity and impaired PGC-1α/β signaling. Critically, one week of intraperitoneal NMN at 500 mg/kg/day restored muscle NAD+ to youthful levels, normalized the nuclear-mitochondrial communication axis, and reversed key features of mitochondrial dysfunction — effectively making 22-month-old muscle resemble that of 6-month-old animals at the transcriptomic and respirometric level. The work cemented NAD+ as a causal, reversible mediator of mitochondrial aging and served as the experimental foundation for subsequent NMN trials in humans. The rapid rescue also demonstrated that NAD+ deficit, not accumulated damage, drives a meaningful portion of the aged phenotype.

For background on the compound studied here, see our NMN precursor reference.

Frequently asked questions

What did Gomes et al. (2013) find about NMN?

Short-term NMN restores aged-mouse muscle NAD+ and reverses pseudohypoxic mitochondrial dysfunction, implicating NAD+ decline as a causal aging driver. Source: Gomes AP, Price NL, Ling AJY, et al. "Declining NAD induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell, 2013.

What kind of study is Gomes 2013?

It is a mechanism study on NMN published in Cell in 2013. Mechanistic mouse study from the Sinclair lab showing that age-related NAD+ decline induces a pseudohypoxic state in which HIF-1α stabilizes under normoxia, disrupting SIRT1-mediated signaling from nucleus to mitochondria and causing mitochondrial-encoded OXPHOS gene expression to fall. Aged (22-month) C57BL/6 mice had ~50% lower muscle NAD+ than young (6-month) controls, paired with reduced mitochondrial respiratory capacity and impaired PGC-1α/β signaling. Critically, one week of intraperitoneal NMN at 500 mg/kg/day restored muscle NAD+ to youthful levels, normalized the nuclear-mitochondrial communication axis, and reversed key features of mitochondrial dysfunction — effectively making 22-month-old muscle resemble that of 6-month-old animals at the transcriptomic and respirometric level. The work cemented NAD+ as a causal, reversible mediator of mitochondrial aging and served as the experimental foundation for subsequent NMN trials in humans. The rapid rescue also demonstrated that NAD+ deficit, not accumulated damage, drives a meaningful portion of the aged phenotype.

Where can I read the full Gomes 2013 paper?

The primary source is available on PubMed (PMID 24360282) and via DOI 10.1016/j.cell.2013.11.037.

Access the full paper

Related research